Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  agatolimod sodium
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-20 of 20 for your search:
Start Over
Phase I/II Study of CpG 7909 and Trastuzumab (Herceptin) in Women With Metastatic Breast Cancer Refractory to Trastuzumab and Chemotherapy
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CPGI-C005, CPGI-C005-CPG7909, CPGI-WIRB-20011156, NCI-V02-1697
CPG 7909 in Patients Wih Stage IV Renal Cell Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: C010, CO10, A8501022, NCT00043407
Phase I/II Randomized Study of CpG 7909 in Patients With Stage IB-IVA Cutaneous T-Cell Lymphoma. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information.
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: UCLA-030104201A, CPGI-C014, CPGI-CPG7909-C014, NCT00091208
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: IRB-13063, 80057, LYMNHL0014, NCT00185965
CpG 7909, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Treatment
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LS0382, 703-04, MAYO-LS0382, MAYO-IRB-703-04, NCT00438880
CPG 7909 Injection in Non-Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C017, ProMune, CO17, A8501017, NCT00070629
CPG 7909 Injection in Melanoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C023, CO23, A8501023, NCT00070642
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: C016, CO16, A8501015, NCT00043368
Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 16 and over
Sponsor: NCI, Other
Protocol IDs: 10M-03-3, NCI-2012-02593, CDR0000367485, LAC-USC-10M033, LAC-USC-IRB-942010, NCI-6451, 6451, NCT00085189
Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A8501006, NCT00321815
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSU-08153, NCI-2011-03157, PFIZER-GA8501YF, 2008C0116, NCT00824733
A Phase II Intratumoral Injection PF-3512676 Plus Local Radiation in Low-Grade B-Cell Lymphomas
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: LYMNHL0064, SU-03272009-2038, 14820, NCT00880581
Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD 2000-018, NCT00112229
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously Treated
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 200402002, NCT00233506
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: LUD2003-022;NYU05-120;CUMC9147, NCT00299728
Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 04-173, NCI-2009-00159, PCI-IRB-0607048, CDR0000544402, PCI-04173, 7357, NCT00471471
CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: 05-140, 1R01CA112198-01, NCT00819806
Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 55
Sponsor: NCI, Other
Protocol IDs: City of Hope 03121, R01CA077544, P30CA033572, CHNMC-03121, CDR0000599724, NCI-2010-01227, 03121, NCT00722839
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Phase: Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Status: Closed
Age: 18 to 75
Sponsor: NCI, Other
Protocol IDs: 12022, NCI-2012-00589, NCT01588015
Start Over